Helicobacter pylori and gastroesophageal reflux disease: A review of this intriguing relationship

Diseases of the Esophagus

Volumn 22, Issue 3, 2009, Pages 256-263

  Canzi Almada De Souza, Raquel ^a   Hermênio Cavalcante Lima, José ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Gastroesophageal reflux; Helicobacter infection; Helicobacter pylori; Immunology

Indexed keywords

CAGA PROTEIN; GASTRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UREASE; VACUOLATING TOXIN;

BACTERIAL IMMUNITY; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CYTOKINE PRODUCTION; GASTRIN RELEASE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID SECRETION; STOMACH PH;

CYTOKINES; GASTRIC ACID; GASTRIC MUCOSA; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, INNATE;

EID: 65349165902     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2008.00911.x     Document Type: Review

References (77)

1. Schutze K, Hentschel E, Dragosics B, Hirschl A M. Helicobacter pylori reinfection with identical organisms: Transmission by the patients' spouses. Gut 1995; 36: 831-3.
2. Labenz J, Blum A L, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
3. Blot W J, Devesa S S, Kneller R W, Fraumeni J F Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-9.
4. el-Serag H B, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327-33.
5. Penagini R, Carmagnola S, Cantu P. Review article: Gastro-oesophageal reflux disease -pathophysiological issues of clinical relevance. Aliment Pharmacol Ther 2002; 16 (Suppl 4): 65-71.
6. Nguyen N Q, Holloway R H. Gastroesophageal reflux disease. Curr Opin Gastroenterol 2003; 19: 373-8.
7. Richter J. Do we know the cause of reflux disease? Eur J Gastroenterol Hepatol 1999; 11 (Suppl 1): S3-9.
8. Cadiot G. Reflux gastro-oesophagien (1). Necessite d'une approache therapeutique pragmatique. Presse Med 1997; 26: 1207-8.
9. Beales I, Blaser M J, Srinivasan S et al. Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells. Gastroenterology 1997; 113: 465-71.
10. Takashima M, Furuta T, Hanai H, Sugimura H, Kaneko E. Effects of Helicobacter pylori infection on gastric acid secretion and serum gastrin levels in Mongolian gerbils. Gut 2001; 48: 765-73.
11. Modlin I M, Sachs G, Wright N, Kidd M. Edkins and a century of acid suppression. Digestion 2005; 72: 129-45.
12. Boyd E J. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. Am J Gastroenterol 1996; 91: 1539-43.
13. El-Omar E M, Oien K, El-Nujumi A et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24.
14. Beales I L. Effect of cytokines on acid secretion and gastrin secretion in Helicobacter pylori infection and aspirin-induced gastritis. Scand J Gastroenterol 1998; 33: 1230-2.
15. Peek R M Jr, Blaser M J, Mays D J et al. Helicobacter pylori strain-specific genotypes and modulation of the gastric epithelial cell cycle. Cancer Res 1999; 59: 6124-31.
16. Peek R M Jr, Wirth H P, Moss S F et al. Helicobacter pylori alters gastric epithelial cell cycle events and gastrin secretion in Mongolian gerbils. Gastroenterology 2000; 118: 48-59.
17. Koike T, Ohara S, Sekine H et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 49: 330-4.
18. Yamaji Y, Mitsushima T, Ikuma H et al. Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: Analysis of 5732 Japanese subjects. Gut 2001; 49: 335-40.
19. Sipponen P, Hyvarinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol Suppl 1993; 196: 3-6.
20. Vicari J J, Peek R M, Falk G W et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-7.
21. O'Connor H J, Cunnane K. Helicobacter pylori and gastro-oesophageal reflux disease -a prospective study. Ir J Med Sci 1994; 163: 369-73.
22. El-Serag H B, Sonnenberg A, Jamal M M, Inadomi J M, Crooks L A, Feddersen R M. Corpus gastritis is protective against reflux oesophagitis. Gut 1999; 45: 181-5.
23. Koike T, Ohara S, Sekine H et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999; 94: 3468-72.
24. Shirota T, Kusano M, Kawamura O, Horikoshi T, Mori M, Sekiguchi T. Helicobacter pylori infection correlates with severity of reflux esophagitis: With manometry findings. J Gastroenterol 1999; 34: 553-9.
25. Zentilin P, Iiritano E, Vignale C et al. Helicobacter pylori infection is not involved in the pathogenesis of either erosive or non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 17: 1057-64.
26. Newton M, Bryan R, Burnham W R, Kamm M A. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut 1997; 40: 9-13.
27. Anderson L A, Murphy S J, Johnston B T et al. Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: Results from de FINBAR case-control study. Gut 2007; 19: 734-9.
28. Ramus J R, Gatenby P A, Caygill C P, Watson A. Helicobacter pylori infection and severity of reflux-induced esophageal disease in a cohort of patients with columnar-lined esophagus. Dig Dis Sci 2007; 52: 2821-5.
29. Kiltz U, Pfaffenbach B, Schmidt W E, Adamek R J. The lack of influence of CagA positive Helicobacter pylori strains on gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2002; 14: 979-84.
30. De Koster E, Ferhat M, Deprez C, Deltenre S M. H.pylori, gastric histology and gastro-esophageal reflux disease. Gastroenterology 1995; 108 (Suppl): A81 (Abstract).
31. Ackermark P, Kuipers E J, Wolf C et al. Colonization with cagA-positive Helicobacter pylori strains in intestinal metaplasia of the esophagus and the esophagogastric junction. Am J Gastroenterol 2003; 98: 1719-24.
32. Weston A P, Badr A S, Topalovski M, Cherian R, Dixon A, Hassanein R S. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000; 95: 387-94.
33. Kudo M, Gutierrez O, El-Zimaity H M et al. CagA in Barrett's oesophagus in Colombia, a country with a high prevalence of gastric cancer. J Clin Pathol 2005; 58: 259-62.
34. Pereira-Lima J C, Marques D L, Pereira-Lima L F, Hornos A P, Rota C. The role of cagA Helicobacter pylori strains in gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2004; 16: 643-7.
35. Queiroz D M, Rocha G A, Oliveira C A et al. Role of corpus gastritis and cagA-positive Helicobacter pylori infection in reflux esophagitis. J Clin Microbiol 2002; 40: 2849-53.
36. Fallone C A, Barkun A N, Mayrand S et al. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori. Aliment Pharmacol Ther 2004; 20: 761-8.
37. Feldman M, Cryer B, Lee E. Effects of Helicobacter pylori gastritis on gastric secretion in healthy human beings. Am J Physiol 1998; 274 (6 Pt 1): G1011-7.
38. Hamada H, Haruma K, Mihara M et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: Impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14: 729-35.
39. Cremonini F, Di Caro S, Delgado-Aros S et al. Meta-analysis: The relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 18: 279-89.
40. Raghunath A S, Hungin A P, Wooff D, Childs S. Systematic review: The effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004; 20: 733-44.
41. Guliter S, Kandilci U. The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. J Clin Gastroenterol 2004; 38: 750-5.
42. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: A post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97: 2992-7.
43. Genta R M, Lew G M, Graham D Y. Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 1993; 6: 281-9.
44. Rauws E A, Langenberg W, Houthoff H J, Zanen H C, Tytgat G N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33-40.
45. Haruma K, Mihara M, Okamoto E et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment Pharmacol Ther 1999; 13: 155-62.
46. Ott E A, Mazzoleni L E, Edelweiss M I et al. Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: A randomized, investigator-blinded, placebo-controlled trial. Aliment Pharmacol Ther 2005; 21: 1231-9.
47. Ito L S, Oba-Shinjo S M, Marie S K et al. Lifestyle factors associated with atrophic gastritis among Helicobacter pylori-seropositive Japanese-Brazilians in Sao Paulo. Int J Clin Oncol 2003; 8: 362-8.
48. Kato I, Vivas J, Plummer M et al. Environmental factors in Helicobacter pylori-related gastric precancerous lesions in Venezuela. Cancer Epidemiol Biomarkers Prev 2004; 13: 468-76.
49. Lee S A, Kang D, Shim K N, Choe J W, Hong W S, Choi H. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol 2003; 13: 162-8.
50. Machida-Montani A, Sasazuki S, Inoue M et al. Association of Helicobacter pylori infection and environmental factors in non-cardia gastric cancer in Japan. Gastric Cancer 2004; 7: 46-53.
51. Shimoyama T, Everett S M, Fukuda S, Axon A T, Dixon M F, Crabtree J E. Influence of smoking and alcohol on gastric chemokine mRNA expression in patients with Helicobacter pylori infection. J Clin Pathol 2001; 54: 332-4.
52. Segal E D. Consequences of attachment of Helicobacter pylori to gastric cells. Biomed Pharmacother 1997; 51: 5-12.
53. Xia H H, Talley N J. Natural acquisition and spontaneous elimination of Helicobacter pylori infection: Clinical implications. Am J Gastroenterol 1997; 92: 1780-7.
54. Smith M F Jr, Mitchell A, Li G et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem 2003; 278: 32552-60.
55. Keates S, Hitti Y S, Upton M, Kelly C P. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology 1997; 113: 1099-109.
56. Viala J, Chaput C, Boneca I G et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004; 5: 1166-74.
57. Isomoto H, Mizuta Y, Miyazaki M et al. Implication of NF-kappaB in Helicobacter pylori-associated gastritis. Am J Gastroenterol 2000; 95: 2768-76.
58. Peek R M Jr. Helicobacter pylori strain-specific modulation of gastric mucosal cellular turnover: Implications for carcinogenesis. J Gastroenterol 2002; 37 (Suppl 13): 10-6.
59. Crabtree J E, Taylor J D, Wyatt J I et al. Mucosal IgA recognition of Helicobacter pylori 120kDa protein, peptic ulceration, and gastric pathology. Lancet 1991; 338 (8763): 332-5.
60. Garcia-Gonzalez M A, Lanas A, Santolaria S, Crusius J B, Serrano M T, Pena A S. The polymorphic IL-1B and IL-1RN genes in the aetiopathogenesis of peptic ulcer. Clin Exp Immunol 2001; 125: 368-75.
61. El-Omar E M, Carrington M, Chow W H et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404 (6776): 398-402.
62. El-Omar E M, Carrington M, Chow W H et al. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 2001;412 (6842): 99.
63. Machado J C, Figueiredo C, Canedo P et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125: 364-71.
64. El-Omar E M, Rabkin C S, Gammon M D et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-201.
65. Queiroz D M, Guerra J B, Rocha G A et al. IL1B and IL1RN polymorphic genes and Helicobacter pylori cagA strains decrease the risk of reflux esophagitis. Gastroenterology 2004; 127: 73-9.
66. Peterson R A 2nd, Hoepf T, Eaton K A. Adoptive transfer of splenocytes in SCID mice implicates CD4+ T cells in apoptosis and epithelial proliferation associated with Helicobacter pylori-induced gastritis. Comp Med 2003; 53: 498-509.
67. Akhiani A A, Schon K, Franzen L E, Pappo J, Lycke N. Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immunol 2004; 172: 5024-33.
68. Raghavan S, Holmgren J. CD4+CD25+ suppressor T cells regulate pathogen induced inflammation and disease. FEMS Immunol Med Microbiol 2005; 44: 121-7.
69. Lundgren A, Suri-Payer E, Enarsson K, Svennerholm A M, Lundin B S. Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun 2003; 71: 1755-62.
70. Lundgren A, Stromberg E, Sjoling A et al. Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun 2005; 73: 523-31.
71. Raghavan S, Fredriksson M, Svennerholm A M, Holmgren J, Suri-Payer E. Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin Exp Immunol 2003; 132: 393-400.
72. Evans D J Jr, Evans D G, Takemura T et al. Characterization of a Helicobacter pylori neutrophil-activating protein. Infect Immun 1995; 63: 2213-20.
73. Bodger K, Bromelow K, Wyatt J I, Heatley R V. Interleukin 10 in Helicobacter pylori associated gastritis: Immunohistochemical localisation and in vitro effects on cytokine secretion. J Clin Pathol 2001; 54: 285-92.
74. Fox J G, Beck P, Dangler C A et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med 2000; 6: 536-42.
75. El-Omar E M. The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut 2001; 48: 743-7.
76. Israel D A, Salama N, Arnold C N et al. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses. J Clin Invest 2001; 107: 611-20.
77. Israel D A, Peek R M Jr. The role of persistence in Helicobacter pylori pathogenesis. Curr Opin Gastroenterol 2006; 22: 3-7.